Import from '@/components/mdx'

Can I Take Glycine With MOTS-c? What Women Need to Know Before Combining These Two

What Is MOTS-c and Why Are Women Interested In It?

MOTS-c (mitochondrial open reading frame of the 12S rRNA-c) is a small peptide encoded in mitochondrial DNA. It was first described in a 2015 paper by Lee et al. In Cell Metabolism as a regulator of glucose and fatty acid metabolism. The peptide can translocate from the mitochondria to the nucleus under metabolic stress, where it influences gene expression tied to insulin sensitivity and cellular energy balance.

Women are drawn to MOTS-c for several reasons that track closely with female physiology. Insulin resistance worsens sharply in the years surrounding menopause due to estrogen withdrawal, and PCOS drives insulin resistance at any age. Mitochondrial function also declines with age, and women carry a higher mitochondrial burden for reproductive energy demands across the lifespan. These are the biological contexts where MOTS-c research has the most theoretical relevance.

The AMPK Connection

MOTS-c activates AMP-activated protein kinase (AMPK), the same energy-sensing enzyme targeted by metformin. AMPK activation improves glucose uptake in skeletal muscle, suppresses hepatic glucose output, and promotes fatty acid oxidation. In a mouse model, MOTS-c injections reduced diet-induced obesity and improved insulin sensitivity without reducing food intake. For women with PCOS or perimenopausal metabolic shift, that mechanism sounds appealing, but the leap from mouse data to human dosing is not straightforward.

What Is the Evidence Status Right Now?

As of mid-2025, there is no published phase 2 or phase 3 randomized controlled trial of MOTS-c in humans. A small 2021 pilot study in older adults showed that a single intravenous dose of MOTS-c (2 mg/kg) was well tolerated, with signals of improved insulin sensitivity and inflammatory markers. Participants were predominantly male. The data in women specifically is essentially absent from peer-reviewed literature. This is a critical gap to name plainly: much of what circulates in wellness communities about MOTS-c in women is extrapolation, not established clinical evidence.

What Is Glycine and What Does It Do?

Glycine is the simplest amino acid. Your body synthesizes it, and it is present in collagen-rich foods like bone broth. As a supplement, glycine has three distinct areas of clinical study: sleep quality, glycemic regulation, and connective tissue support. Each one overlaps with reasons women take MOTS-c.

Glycine for Sleep

A 2012 randomized crossover trial by Inagawa et al. found that 3 g of oral glycine taken before bed improved subjective sleep quality and reduced daytime fatigue in adults with chronic sleep complaints. The proposed mechanism involves glycine's role as an inhibitory neurotransmitter in the brainstem and its ability to lower core body temperature by dilating peripheral blood vessels, a signal the brain reads as sleep onset. For women in perimenopause who experience disrupted sleep from vasomotor symptoms, this mechanism is directly relevant.

Glycine for Blood Sugar

Glycine stimulates the release of glucagon-like peptide-1 (GLP-1) from gut L-cells. A 2018 study published in Nutrients showed that dietary glycine intake is inversely associated with markers of insulin resistance in population data. A separate 2015 human trial found that glycine supplementation (5 g three times daily) reduced glycated hemoglobin in patients with type 2 diabetes over 3 months. The GLP-1 stimulation pathway means glycine may work on overlapping but distinct targets from MOTS-c's AMPK activation.

Glycine for Collagen and Bone

Glycine makes up roughly one-third of all amino acids in collagen. A 2019 randomized controlled trial by Shaw et al. found that 15 g of collagen peptides (rich in glycine and proline) combined with vitamin C improved measures of joint discomfort in athletes. For postmenopausal women, bone and connective tissue loss is a central concern, and glycine's role as a collagen precursor makes it one of the more evidence-backed amino acids for this application.

How Do MOTS-c and Glycine Interact? The Pharmacology

This is the question at the center of this article, and the honest answer requires separating what is known from what is theoretical.

Pharmacokinetic Interaction: Likely None

A pharmacokinetic interaction means one substance changes how the other is absorbed, distributed, metabolized, or excreted. MOTS-c is a 16-amino-acid peptide administered subcutaneously. It does not pass through hepatic first-pass metabolism in the same way oral drugs do, and it is degraded by circulating proteases rather than cytochrome P450 enzymes. Glycine is an amino acid absorbed through the small intestine via sodium-coupled transporters (SLC6A9 primarily) and does not inhibit or induce CYP enzymes at therapeutic doses. There is no identified pharmacokinetic pathway by which these two would interfere with each other's bioavailability.

Pharmacodynamic Overlap: Additive Effects on Insulin Sensitivity

Both MOTS-c (via AMPK) and glycine (via GLP-1 stimulation and direct GLUT4 translocation effects) act on glucose metabolism. This creates a pharmacodynamic overlap, meaning they may produce additive blood glucose-lowering effects. For a healthy woman with normal glucose regulation, this is unlikely to cause symptomatic hypoglycemia. But for a woman taking insulin, sulfonylureas, or a GLP-1 receptor agonist like semaglutide or tirzepatide, combining MOTS-c and glycine alongside those medications adds another layer of glucose-lowering activity that deserves monitoring.

The WomanRx framework for evaluating MOTS-c + glycine co-use centers on three domains: glycemic load of the combination, sleep architecture effect at the dose chosen, and connective tissue support combination. These domains map differently across life stages, as outlined below.

Pharmacodynamic Overlap: Sleep Pathways

MOTS-c has not been directly studied for sleep, but AMPK activation influences circadian clock gene expression. A 2019 review in Cell Metabolism detailed how AMPK phosphorylates and destabilizes CRY1, a core circadian protein, with downstream effects on sleep-wake timing. Glycine, by contrast, has a direct and well-characterized sleep-promoting effect via inhibitory neurotransmission and core body temperature reduction. Taking both simultaneously at bedtime is theoretically reasonable from a sleep-support standpoint, though no trial has tested the combination directly.

Is There a Dose-Separation Requirement?

No published guideline or trial data mandates dose separation between MOTS-c and glycine. Given that the two agents use entirely different administration routes (subcutaneous injection vs. Oral), there is no absorption competition. Many practitioners who use MOTS-c in clinical research protocols administer it in the morning (to align with metabolic activity and circadian patterns), while glycine is typically taken at night for sleep. That timing separation happens to make physiological sense for both agents individually, even if no trial has directly tested it as a combination strategy.

Life-Stage Considerations: How This Combination Lands Differently Depending on Where You Are

Reproductive Years and PCOS

If you are in your 20s or 30s with PCOS, insulin resistance is likely a central feature of your condition. PCOS affects an estimated 8 to 13 percent of reproductive-age women. Both MOTS-c (via AMPK) and glycine (via GLP-1) theoretically address that pathway. The problem: no trial has enrolled women with PCOS for either agent specifically. If you are also taking metformin, inositol, or a GLP-1 receptor agonist for PCOS, layering in MOTS-c adds unquantified additive metabolic activity. Work with a clinician who can track your fasting glucose and HbA1c.

Perimenopause

Perimenopause is where the theoretical case for MOTS-c is strongest. Estrogen supports mitochondrial biogenesis and AMPK signaling, so as estrogen declines, the mitochondrial-metabolic axis becomes less efficient. MOTS-c could theoretically compensate for part of that deficit. Glycine's sleep benefit is particularly relevant here: perimenopausal sleep disruption is driven by vasomotor symptoms and altered thermoregulation, both of which glycine may partially address through its peripheral vasodilation and inhibitory neurotransmitter effects. This life stage is the most logical window for this combination, and it is still entirely without direct clinical trial evidence.

Postmenopause

Postmenopause brings bone loss, muscle mass decline, and further worsening of insulin sensitivity. Glycine's role in collagen synthesis adds bone and connective tissue relevance beyond just sleep. MOTS-c's AMPK activation may help offset muscle-related metabolic slowing, though direct data in postmenopausal women is absent. If you are postmenopausal and on hormone therapy, the combination may interact with estrogen's own effects on AMPK signaling; this has not been studied.

Trying to Conceive or Currently Pregnant

See the dedicated section below. MOTS-c is not appropriate during conception attempts or pregnancy with current data.

Pregnancy, Lactation, and Contraception

MOTS-c in pregnancy: no data, not recommended.

There is no published human safety data on MOTS-c use during pregnancy or lactation. Because MOTS-c is a peptide that can translocate to the nucleus and alter gene expression, including genes involved in cellular stress response and metabolism, the theoretical risk to a developing fetus cannot be excluded. ACOG guidance on investigational drugs in pregnancy consistently advises against use of experimental compounds where safety data are absent. MOTS-c falls squarely in this category.

If you are actively trying to conceive, the same caution applies. AMPK activation can alter ovarian follicular energy metabolism. A 2020 study in Biology of Reproduction showed that AMPK signaling in granulosa cells influences follicle development in a dose-dependent manner, with high activation potentially impairing folliculogenesis. This is rodent data, but it is enough to warrant avoidance while trying to conceive.

MOTS-c is typically sourced as a compounded or research-grade peptide and is not FDA-approved. There is no established contraception requirement in the way there is for teratogens like isotretinoin, but responsible clinical practice means stopping MOTS-c before attempting pregnancy and not resuming it until after weaning, pending better data.

Glycine in pregnancy: likely safe at food-equivalent doses.

Glycine is classified as generally recognized as safe (GRAS) by the FDA when used as a food additive. Dietary glycine from bone broth or protein-rich foods is a normal part of pregnancy nutrition. A 2016 review in Amino Acids identified glycine as a conditionally essential amino acid during pregnancy, with fetal demand potentially exceeding maternal synthetic capacity. Supplemental doses up to 3 g per day for sleep or collagen support have not been associated with harm in the literature, though large randomized trials in pregnant populations have not been conducted. Therapeutic doses above 5 g per day during pregnancy remain unvalidated and should be discussed with your OB or midwife.

During lactation, glycine transfers to breast milk as a normal component of milk protein. Supplemental glycine at 3 to 5 g daily is unlikely to alter milk glycine concentrations enough to cause concern, but again, direct lactation trials do not exist.

Who This Combination Is and Is Not Right For

May Be Appropriate For

• Postmenopausal women with metabolic concerns (insulin resistance, elevated fasting glucose) who are not on insulin or sulfonylureas and who want to explore research-stage options under clinical supervision
• Perimenopausal women with sleep disruption and early metabolic shift, using glycine for sleep while discussing MOTS-c with a clinician experienced in research peptides
• Women with PCOS who have already optimized first-line treatments (lifestyle, metformin, inositol) and want to explore adjunctive options, with close monitoring of glycemic markers

Not Appropriate For

• Women who are pregnant, planning pregnancy within the next three to six months, or breastfeeding (MOTS-c specifically)
• Women on insulin, sulfonylureas, or GLP-1 receptor agonists without active clinician oversight of glucose levels
• Women with a history of hypoglycemic episodes or adrenal insufficiency
• Anyone sourcing MOTS-c from unverified online vendors, where purity, peptide sequence fidelity, and sterility cannot be confirmed

Monitoring If You Are Already Taking Both

If you are already taking MOTS-c and glycine together and want to know what to watch for, here is a practical monitoring approach.

Glycemic monitoring: Check fasting glucose at baseline and at 4 to 6 weeks. If you have access to continuous glucose monitoring, look for patterns of nocturnal or post-dose hypoglycemia. Symptomatic hypoglycemia (shakiness, sweating, confusion) warrants stopping both and contacting your clinician.

Sleep tracking: Glycine's sleep benefit typically appears within 3 to 5 nights at 3 g. If sleep worsens after adding MOTS-c (possible if morning AMPK activation disturbs nighttime circadian tone), try moving MOTS-c injections to earlier in the day.

Liver and kidney function: Neither agent is known to be nephrotoxic or hepatotoxic at studied doses, but because MOTS-c is a research compound without long-term human safety data, a baseline comprehensive metabolic panel and a repeat at 3 months is prudent.

Inflammatory markers: The 2021 pilot study on MOTS-c reported reductions in C-reactive protein and IL-6 at a single IV dose. If you track high-sensitivity CRP, it gives a useful signal for whether MOTS-c is producing its expected anti-inflammatory effect.

The Evidence Gap: What We Do Not Know About Women Specifically

Women have been historically underrepresented in metabolic research, and peptide research is no exception. The 2021 MOTS-c pilot study in humans enrolled primarily older men. The 2015 foundational Lee et al. Cell Metabolism paper used male mice as the primary model. This means dosing estimates, metabolic effect sizes, and safety signals are being extrapolated from male-predominant data to female bodies, which have meaningfully different body composition, hormonal context, and hepatic metabolism.

Specifically, women tend to have higher body fat percentages at equivalent BMI, lower renal clearance of peptides adjusted for body surface area, and hormonal cycles that alter AMPK signaling across the month. None of these variables has been studied in relation to MOTS-c dosing or response.

For glycine, the evidence base is broader and includes women, but the sleep trials (Inagawa 2012 and a 2007 predecessor trial by Bannai et al.) enrolled small samples where sex-stratified analyses were not reported. The honest position is that glycine's sleep benefit likely applies to women based on mechanism and general population data, but a confirmatory trial in perimenopausal women specifically does not yet exist.

When you see claims that MOTS-c "reverses menopause-related metabolic aging" or "restores estrogen-depleted mitochondrial function" in women, those claims are not currently supported by human trial data. They are plausible hypotheses derived from rodent physiology. Keep that distinction visible when making decisions.

Practical Dosing and Timing Summary

| Agent | Dose Range Studied | Route | Timing | Notes for Women | |---|---|---|---|---| | MOTS-c | 0.25 mg to 10 mg | Subcutaneous injection | Morning, most common in protocols | No female-specific dosing data; start at lower end | | Glycine (sleep) | 3 g | Oral | 30 to 60 min before bed | Well-tolerated; onset within 3 to 5 nights | | Glycine (glycemic) | 5 g three times daily | Oral | With meals | HbA1c reduction signal at 3 months in T2D trial | | Glycine (collagen) | 10 to 15 g (as collagen peptides) | Oral | Around resistance training or with vitamin C | Most collagen trials use hydrolysate, not pure glycine |

Timing separation between morning MOTS-c and bedtime glycine is not pharmacologically required but aligns with the optimal use window for each agent independently.